文献速递糖尿病肥胖与代谢综合征

Roux-en-Y胃旁路术后2型糖尿病长期缓解与复发的预测

Long-term Relapse of Type 2 Diabetes After Roux-en-Y Gastric Bypass: Prediction and Clinical Relevance.
PubMed 文献 · Diabetes Care · 2018-08-06

该研究回顾性纳入175例接受Roux-en-Y胃旁路术(RYGB)的2型糖尿病患者并随访5年,利用机器学习开发了整合基线及术后1年参数的5y-Ad-DiaRem评分,用于预测5年糖尿病缓解(5y-DR)。该评分预测准确性高(AUROC 90%,准确率85%),优于DiaRem和Advanced-DiaRem,并在三个独立欧洲队列中得到验证。

要点

  • 5y-Ad-DiaRem评分可准确预测RYGB术后5年糖尿病缓解,AUROC达90%。
  • 评分整合基线(糖尿病病程、降糖药数量、HbA1c)及术后1年参数。
  • 5y-Ad-DiaRem优于DiaRem和Advanced-DiaRem,并正确重分类部分误判患者。

核心结论

  • 5y-Ad-DiaRem能准确预测RYGB术后5年糖尿病缓解,并有助于识别复发风险患者。
  • 使用该评分可能有助于术后第1年后的个体化护理,以最大化减重、限制体重反弹并预防复发。

研究设计与样本

  • 回顾性纳入175例接受RYGB的2型糖尿病患者,随访5年,利用机器学习算法开发评分。
  • 评分基于组间显著差异变量及比值比构建,并在三个欧洲国家的独立RYGB队列中验证。

主要发现

  • 与5y-DR患者相比,5年后复发患者基线2型糖尿病更严重,术后第1年减重显著更少,之后体重反弹更多。
  • 5y-Ad-DiaRem预测5y-DR的AUROC为90%,准确率为85%。
  • DiaRem的AUROC为81%、准确率79%;Advanced-DiaRem的AUROC为84%、准确率78%。
  • 5y-Ad-DiaRem正确重分类了39例中被DiaRem误判的13例患者。
  • 5y-Ad-DiaRem的稳健性在独立队列中得到确认。

关键数值与推荐

  • 5y-Ad-DiaRem包含基线参数:糖尿病病程、降糖药数量、HbA1c。
  • 5y-Ad-DiaRem包含术后1年参数:血糖、降糖药数量、缓解状态、第1年减重。
  • 预测5y-DR的AUROC为90%、准确率85%,优于DiaRem(AUROC 81%、准确率79%)和Advanced-DiaRem(AUROC 84%、准确率78%)。

临床怎么用

  • 该评分可能有助于识别RYGB术后糖尿病复发风险患者。
  • 使用该评分可能有助于术后第1年后个体化护理,以最大化减重、限制体重反弹并预防复发。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Roux-en-Y gastric bypass (RYGB) induces type 2 diabetes remission (DR) in 60% of patients at 1 year, yet long-term relapse occurs in half of these patients. Scoring methods to predict DR outcomes 1 year after surgery that include only baseline parameters cannot accurately predict 5-year DR (5y-DR). We aimed to develop a new score to better predict 5y-DR. RESEARCH DESIGN AND METHODS: We retrospectively included 175 RYGB patients with type 2 diabetes with 5-year follow-up. Using machine learning algorithms, we developed a scoring method, 5-year Advanced-Diabetes Remission (5y-Ad-DiaRem), predicting longer-term DR postsurgery by integrating medical history, bioclinical data, and antidiabetic treatments. The scoring method was based on odds ratios and variables significantly different between groups. This score was further validated in three independent RYGB cohorts from three European countries. RESULTS: Compared with 5y-DR patients, patients who had relapsed after 5 years exhibited more severe type 2 diabetes at baseline, lost significantly less weight during the 1st year after RYGB, and regained more weight afterward. The 5y-Ad-DiaRem includes baseline (diabetes duration, number of antidiabetic treatments, and HbA1c) and 1-year follow-up parameters (glycemia, number of antidiabetic treatments, remission status, 1st-year weight loss). The 5y-Ad-DiaRem was accurate (area under the receiver operating characteristic curve [AUROC], 90%; accuracy, 85%) at predicting 5y-DR, performed better than the Diabetes Remission score (DiaRem) and the Advanced-DiaRem (AUROC, 81% and 84%; accuracy, 79% and 78%, respectively), and correctly reclassified 13 of 39 patients misclassified with the DiaRem. The 5y-Ad-DiaRem robustness was confirmed in the independent cohorts. CONCLUSIONS: The 5y-Ad-DiaRem accurately predicts 5y-DR and appears relevant to identify patients at risk for relapse. Using this score could help personalize patient care after the 1st year post-RYGB to maximize weight loss, limit weight regains, and prevent relapse.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Debédat J, Sokolovska N, Coupaye M, et al. Long-term Relapse of Type 2 Diabetes After Roux-en-Y Gastric Bypass: Prediction and Clinical Relevance. Diabetes Care. 2018. PMID: 30082327. doi:10.2337/dc18-0567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。